These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 16752308)

  • 1. Allergy, Allergic Inflammation and Asthma--Keystone Symposium. Pharmacological targets in allergic inflammation and asthma.
    Kierstein S
    IDrugs; 2006 Jun; 9(6):405-8. PubMed ID: 16752308
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanisms in allergic airway inflammation - lessons from studies in the mouse.
    Shum BO; Rolph MS; Sewell WA
    Expert Rev Mol Med; 2008 May; 10():e15. PubMed ID: 18503727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulin E: role in asthma and allergic disease: lessons from the clinic.
    Owen CE
    Pharmacol Ther; 2007 Jan; 113(1):121-33. PubMed ID: 17000005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease.
    Mitchell J; Dimov V; Townley RG
    Curr Opin Investig Drugs; 2010 May; 11(5):527-34. PubMed ID: 20419598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New perspectives on mechanisms underlying chronic allergic inflammation and asthma in 2007.
    Broide D
    J Allergy Clin Immunol; 2008 Sep; 122(3):475-80. PubMed ID: 18694589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unanswered questions on omalizumab (Xolair) patient selection and follow-up.
    Lanier B; Marshall GD
    Ann Allergy Asthma Immunol; 2004 Feb; 92(2):198-200. PubMed ID: 14989386
    [No Abstract]   [Full Text] [Related]  

  • 7. The eotaxins in asthma and allergic inflammation: implications for therapy.
    Corrigan C
    Curr Opin Investig Drugs; 2000 Nov; 1(3):321-8. PubMed ID: 11249715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alveolar nitric oxide concentration, small airways inflammation, and targeted asthma therapy: are we there yet?
    Kelly HW
    J Allergy Clin Immunol; 2010 Oct; 126(4):736-7. PubMed ID: 20920762
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of asthma.
    Hawkins GA; Peters SP
    Methods Mol Biol; 2008; 448():359-78. PubMed ID: 18370237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of neuro-immune cross-talk in the regulation of inflammation and remodelling in asthma.
    Veres TZ; Rochlitzer S; Braun A
    Pharmacol Ther; 2009 May; 122(2):203-14. PubMed ID: 19292991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of omalizumab in monozygotic twin sisters with severe allergic asthma.
    Just J; Sahraoui F; Le Gros V; Grimfeld A
    Allergy; 2007 Apr; 62(4):453-4. PubMed ID: 17362261
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma.
    Massanari M; Nelson H; Casale T; Busse W; Kianifard F; Geba GP; Zeldin RK
    J Allergy Clin Immunol; 2010 Feb; 125(2):383-9. PubMed ID: 20159249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with anti-CC chemokine receptor 3 monoclonal antibody or dexamethasone inhibits the migration and differentiation of bone marrow CD34 progenitor cells in an allergic mouse model.
    Ben S; Li X; Xu F; Xu W; Li W; Wu Z; Huang H; Shi H; Shen H
    Allergy; 2008 Sep; 63(9):1164-76. PubMed ID: 18699933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Asthma is a systemic inflammation--not a local disease. Broad anti-inflammatory treatment is necessary].
    Bjermer L
    Lakartidningen; 2009 Jul 22-Aug 4; 106(30-31):1905-8. PubMed ID: 19739445
    [No Abstract]   [Full Text] [Related]  

  • 16. [Omalizumab, an anti-IgE monoclonal antibody to treat severe asthma].
    Michils A; Sternon J
    J Pharm Belg; 2006; 61(3):83-7. PubMed ID: 17058881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.
    Chang TW; Wu PC; Hsu CL; Hung AF
    Adv Immunol; 2007; 93():63-119. PubMed ID: 17383539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-inflammatory effects of seven years treatment with Omalizumab in severe uncontrolled asthmatics.
    Pace E; Ferraro M; Bruno A; Bousquet J; Gjomarkaj M
    Allergy; 2010 Nov; 65(11):1495-6. PubMed ID: 20486917
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma.
    Ozdemir C; Yazi D; Gocmen I; Yesil O; Aydogan M; Semic-Jusufagic A; Bahceciler NN; Barlan IB
    Pediatr Allergy Immunol; 2007 Sep; 18(6):508-15. PubMed ID: 17680909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin E-mediated airway inflammation is active in most patients with asthma.
    Hayden ML
    J Am Acad Nurse Pract; 2007 Sep; 19(9):439-49. PubMed ID: 17760568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.